Interferon-α2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial

Annals of Internal Medicine

Volumn 124, Issue 2, 1996, Pages 212-222

  Hjorth, Martin ^a  

^a Department of Pediatrics   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

MELPHALAN; PREDNISONE; RECOMBINANT ALPHA2B INTERFERON;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE MYELOMA; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENAL ARTERY THROMBOSIS; STROKE; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030042482     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-124-2-199601150-00004     Document Type: Article

References (28)

1. Bergsagel DE. Chemotherapy of myeloma drug combinations versus single agents, an overview, and comments on acute leukemia in myeloma. Hematol Oncol 1988;6:159-66
2. Hjorth M, Hellquist L, Holmberg E, Magnusson B, Rödjer S, Westin J. Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan-prednisone. Br J Haematol 1990,74:185-91
3. Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma an overview of published trials J Clin Oncol. 1992,10 334-42
4. Alexanian R, Dimopoulos M. The treatment of multiple myeloma. N Engl J Med. 1994,330 484-9
5. Metlstedt H, Åhre A, Björkholm M, Holm G, Johansson B, Strander H. Interferon therapy in myelomatosis Lancet 1979;1 245-7
6. Quesada JR, Alexanian R, Hawkins M, Barlogie B, Borden E, Itri L, et al. Treatment of multiple myeloma with recombinant alpha-interferon Blood 1986,67 275-8
7. Cooper MR. Interferons in the management of multiple myeloma Semin Oncol. 1988,15(5 Suppl 5) 21-5
8. Åhre A, Björkholm M, Mellstedt H, Brenning G, Engstedt L, Gahrton G, et al. Human leukocyte interferon and intermittent high-dose melphalan-prednisone administration in the treatment of multiple myeloma a randomized clinical trial from the Myeloma Group of Central Sweden Cancer Treat Rep 1984;68 1331-8
9. Ludwig H, Cortelezzi A, Scheithauer W, Van Camp BG, Kuzmits R, Fillet G, et al. Recombinant interferon alfa-2c versus polychemotherapy (VMCP) for treatment of multiple myeloma a prospective randomized trial Eur J Cancer Clin Oncol 1986,22:1111-6
10. Cooper MR. A review of the clinical studies of alpha-interferon in the management of multiple myeloma Semin Oncol 1991;18(5 Suppl 7) 18-29.
11. Awisati G, Mandelli F. The role of interferon-alpha in the management of myelomatosis Hematol Oncol Clin North Am 1992;6 395-405.
12. Montuoro A, De Rosa L, De Blasio A, Pacilli L, Petti N, De Laurenzi A. Alpha-2a-interferon/melphalan/prednisone versus melphalan/prednisone in previously untreated patients with multiple myeloma Br J Haematol 1990; 76 365-8
13. Cooper MR, Dear K, McIntyre OR, Ozer H, Ellerton J, Canellos G, et al. A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study J Clin Oncol 1993,11 155-60
14. Österborg A, Björkholm M, Björeman M, Brenning G, Carlson K, Celsing F, et al. Natural interferon-alpha in combination with melphalan/ prednisone versus melphalan/pradnisone in the treatment of multiple myeloma stages II and III a randomized study from the Myeloma Group of Central Sweden. Blood 1993,81 1428-34
15. Mandelli F, Avvisati G, Amadori S, Boccadoro M, Gernone A, Lauta VM, et al. Maintenance treatment with recombinant interferon alfa-2b m patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med 1990,332 1430-4
16. Westin J, Rödjer S, Turesson I, Cortelezzi A, Hjorth M, Zador G. Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma, a randomized study. Br J Haematol. 1996;89.561-8
17. Salmon SE, Crowley JJ, Grogan TM, Finley P, Pugh RP, Barlogie B. Combination chemotherapy, glucocorticosteroids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study J Clin Oncol 1994,12:2405-14
18. Peest D, Deicher H, Coldewey R, Leo R, Bartl R, Bartels H, et al. A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma A prospective trial of the German Myeloma Treatment Group Eur J Cancer 1995,31A:146-51
19. Bergsagel DE, von Wussow P, Alexanian R, Avvisati G, Bataille R, Barlogie B, et al. Interferons in the treatment of multiple myeloma [Letter]. J Clin Oncol. 1990;8:1444-5
20. Hjorth M, Holmberg E, Rödjer S, Westin J. Impact of active and passive exclusions on the results of a clinical trial in multiple myeloma. The Myeloma Group of Western Sweden Br J Haematol. 1992,80 55-61
21. Oken MM, Kyle RA. Strategies for combining interferon with chemotherapy for the treatment of multiple myeloma. Semin Oncol. 1991,18(Suppl 5):30-2.
22. Avvisati G, Boccadoro M, Petrucci MT, Giannarelli D, Frieri R, Gallone G, et al. Interferon alpha as Maintenance Treatment in Multiple Myeloma: The Italian Experience. IV International Workshop on Multiple Myeloma Rochester, MN: Mayo Medical Center, 1993 87-8
23. Browman GP, Rubin S, Walker I, Sicheri D, Belch A, Oreilly S, et al. Interferon-alfa-2b maintenance therapy prolongs progression-free and overall survival in plasma cell myeloma. Results of a randomized trial Proceedings of the Annual Meeting of the American Society of Clinical Oncology 1994;13: 408
24. Ludwig K, Cohen AM, Huber H, Senn H, Gunczler P, Schuller J, et al. Interferon (IFN) with VMCP compared to VMCP for induction and IFN compared to control for remission maintenance in multiple myeloma Proc Annu Meet Am Soc Clin Oncol 1994;13:408.
25. Cunningham D, Powles R, Malpas JS, Milan S, Meldrum M, Viner C, et al. A randomized trial of maintenance therapy with intron-A following high-dose melphalan and ABMT in myeloma [Abstract]. Proc Annu Meet Am Soc Clin Oncol 1993;12 364
26. Belch A, Shelley W, Bergsagel D, Wilson K, Klimo P, White D, et al. A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients. Br J Cancer 1988,57:94-9
27. Rödjer S, Swolin B, Weinfetd A, Westin J. Cytogenetic abnormalities in acute leukemia complicating melphalan-treated multiple myeloma Cancer Genet Cytogenet 1990,48 67-73
28. Sonnenblick M, Rosin A. Cardiotoxicity of interferon A review of 44 cases. Chest 1991,99 557-61.